anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A veterinary composition for treating wound or dermatitis is provided to be safely applied on the skin without side effect. CONSTITUTION: A veterinary composition for treating seborrhoeic dermatitis contains 0.1-0.5 weight parts of red shale with 20,000-90,000 mesh; and veterinarily acceptable carrier. The veterinary composition contains aqueous suspension of the red shale. The aqueous suspension contains veterinarily acceptable purified water, mineral water, spring water, deep sea mineral water, or desalted deep sea mineral water. The formulation of the verterinary composition is an external use formulation. The formulation of the composition is an ointment, mousse, aerosol, gel, cream, liposome-containing hydrogel, suspension, plaster, powder, hydrous plaster, liquid, foaming agent, shampoo, rinse, solid, pack, lotion, soap, or spray.
Carefully consider the potential benefits and risks of indomethacin suppositories and other treatment options before deciding to use indomethacin suppositories. Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5)].

After observing the response to initial therapy with indomethacin, the dose and frequency should be adjusted to suit an individual patient's needs.

Adverse reactions generally appear to correlate with the dose of indomethacin. Therefore, every effort should be made to determine the lowest effective dosage for the individual patient.

SUPPOSITORIES: Indomethacin suppositories are available as 50 mg suppositories for rectal use only. Indomethacin suppositories are not for oral or intravaginal use.
The patients will be organized into two cohorts. Cohort 1 will receive 10 mCi and will be imaged 4 and 6 hours post injection. Cohort 2 will receive 15 millicurie (mCi) and will be imaged 4 and 6 hours post injection. Cohort 2 will be imaged if the optimal protocol identified image quality from cohort 1 does not allow for the resolution of cancer lesions.
In recent years, there have been increasing evidence that tongue strengthening exercises have the ability to improve tongue muscle strength and tongue muscle thickness in the geriatric population. These improvements have a direct impact on the oral phase of swallow, specifically resulting in better orolingual manipulation and propulsion, and increasing intra-oral pressure for better bolus clearance. Reduction in tongue strength and other swallowing parameters can lead to swallowing disorder known as dysphagia. In the healthy ageing population, weakness in swallowing muscles is termed presbyphagia. Geriatric patients have an even higher chance of transitioning from presbyphagia to dysphagia when they become acutely unwell. Studies have also shown that deterioration of the whole-body muscle strength is associated with poorer oral function. Additionally, other studies have also shown that a lower isometric tongue strength might represent diminished functional reserves, which may increase the risk of dysphagia once an insult to the body occurs. There is also evidence that people who have episodes of aspiration have significantly weaker tongue strength at both the anterior and posterior regions. Thus, frail geriatric adults who have weaker skeletal muscles are at a higher risk of developing dysphagia. The tongue is amendable to therapy but current practices in Singapore lack an objective measure. Conventional dysphagia oromotor exercises employ the use of a tongue depressor. This method lacks a quantifiable measure to track outcome and is quite subjective to individual therapists. There is also a lack of practice guideline on recommended resistive load and frequency of exercise in the geriatric population in the acute setting. Other than outcome measures and practice guidelines, there is also a lack of research investigating the correlation of tongue strength and functional status. A few studies have explored the effects of different resistive load used in tongue strengthening exercises, although it was recommended to use a resistive load between 60% to 80% for more positive and extrinsic feedback, and for target population with a lower frustration threshold. Studies also used a longer timeframe of 3-4 weeks of rehabilitation to attain significant effects from skeletal muscle exercise. This, however, is not realistic in the acute geriatric setting in Singapore where the mean length of stay is 10 days. Thus, this study is an exploratory study to investigate the efficacy of using IOPI in this population to improve swallowing function and tongue strength. This study also aims to investigate if a correlation exists between IOPI reading and functional status.
Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
Diagnostic therapeutic agents are useful for photoacoustic imaging (PAI) and photothermal therapy (PTT) applications. Diagnostic therapeutic agents may include small molecule organic compounds that have absorption in the Near Infrared (NIR) diagnostic window (700-900 nm). The compound can be prepared into biocompatible Organic Nanoparticles (ONP). Diagnostic therapeutic agents are useful in PAI and PAI-directed PTT applications. Diagnostic therapeutic agents may be applied to a patient and the tumor site determined using in vivo imaging techniques. After the tumor location is determined, the tumor site can be irradiated with near infrared light to stop or inhibit tumor growth.
NEW MATERIAL:The compound of formula I (X is group of formula II or formula III, or its pharmacologically permissible salt. EXAMPLE:Phyllohydroquinone-di-hemifumarate disodium salt. USE:A medicine. A medicine of a stable water-soluble reduced-type vitamin K, capable of solubilizing vitamin K without using a surfactant and a dissolution assistant, reducible in living body to exhibit the activity of reduced-type vitamin K and useful as a preventive and therapeutic agent for diseases or symptoms caused by the deficiency of vitamin K. It is also used as a preparation containing a fat-soluble vitamin K in the form soluble in water. PREPARATION:The objective compound of formula I can be produced either by condensing a compound of formula II with a compound of formula III in a solvent in the presence of a base or by carrying out the condensation reaction and deprotection reaction. The starting compound of formula II can easily be produced at a low cost by reducing phylloquinone or menaquinone. The compound of formula I can be converted to the salt by reacting with a salt such as a solution of NaOH.
Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary vascular resistance (PVR), imposing overload on the right ventricle (RV) and imbalance of the redox state. Our study investigated the influence of treatment with sulforaphane (SFN), found in cruciferous vegetables, on RV remodeling and redox homeostasis in monocrotaline (MCT)-induced PAH. Male Wistar rats were separated into 4 groups: control (CTR); CTR + SFN; MCT; and MCT + SFN. PAH induction was implemented by a single dose of MCT (60 mg/kg intraperitoneally). Treatment with SFN (2.5 mg/kg/day intraperitoneally) started on the seventh day after the MCT injection and persisted for 2 weeks. After 21 days of PAH induction, echocardiographic, hemodynamic, and oxidative stress evaluation was performed. The MCT group showed an increase in RV hypertrophy, RV systolic area, RV systolic, mean pulmonary artery pressure, and PVR and exhibited a decrease in the RV outflow tract acceleration time/ejection time ratio, RV fractional shortening, and tricuspid annular plane systolic excursion compared to CTR ( P < 0.05). SFN-treated PAH attenuated detrimental changes in tricuspid annular plane systolic excursion, mean pulmonary artery pressure, and PVR parameters. Catalase levels and the glutathione/Glutathione disulfide (GSSG) ratio were diminished in the MCT group compared to CTR ( P < 0.05). SFN increased catalase levels and normalized the glutathione/GSSG ratio to control levels ( P < 0.05). Data express the benefit of SFN treatment on the cardiac function of rats with PAH associated with the cellular redox state.
PURPOSE: To obtain a slow acting non-solid ophthalmic composition by including a suspension of fine particles having a specific dissolution pH in a non-solid medium usable for ophthalmic application in a state of formulation and pH to keep the particle insoluble before application and to dissolve the particle by the neutralizing action of lacrimal fluid. CONSTITUTION: This sustained release vehicle for ophthalmic use is a non-solid composition for ophthalmic use containing fine particles of a polymer such as polycarboxylic acid polymer or cationic polymer (preferably cellulose acetate phthalate, etc.) and having a particle diameter of preferably 20-70μm, especially 32-56μm in a state suspended in a non-solid medium suitable for ophthalmic application. The solid particle has a dissolution pH of about 4.5-8.5. The composition has a formulation and pH inhibiting the dissolution of the fine particles before application and restoring the original. pH by the neutralizing action of lacrimal fluid to effect the dissolution of the fine particles.
Participants will receive fremanezumab 675 milligrams (mg) administered as 3 subcutaneous (SC) injections (225 mg/1.5 milliliters \[mL\] each) at randomization (Week 0), Weeks 4, and 8 during the DB treatment period. Participants who complete the DB treatment period and continue into the OL treatment period will receive fremanezumab 675 mg administered as 3 SC injections (225 mg/1.5 mL each) at Weeks 12, 16, and 20 during the OL treatment period.
A automated patient information retrieval system is provided for notifying patients of medical information. The automated patient information retrieval system includes a processor coupled to memory and a telephone interface circuitry. A processor is also coupled to a modem and an I/O interface. The system allows for a medical provider to enter medical information into voice mailboxes. The messages many be time-sensitive wherein the system automatically calls patients to notify of pending medical information in voice mailboxes. The patient then may telephone the system to receive a medical message stored in a patient mailbox. Medical providers may generate custom voice messages or enter predetermined bulletin codes associated with pre-recorded voice messages. Also, medical providers can enter notes associated with medical voice mailboxes which are only accessible by the medical provider. Message integrity and security are enhanced by requiring the patient to enter both a patient identification number and a medical provider identification number.
New methods for rapid, noninvasive determination of sodium ion in vivo are described. The methods are useful for assessing liver and other organ injury based on a nuclear magnetic resonance determination of intracellular and extracellular sodium in the damaged tissue. A shift reagent, TmDOTP5-, is used in vivo to produce baseline resolved peaks of 23Na. Excellent results are achieved with significantly less TmDOTP5- than with other conventional 23Na shift reagents such as DyTTHA3-. In contrast to use in isolated perfused heart tissue, TmDOTP5- solutions are employed in vivo without added calcium ion. The method has been applied to animal burn models. Results show that intracellular sodium ion levels are dramatically increased, thus providing a rapid assessment of liver function. Similar methods may be applied to the determination of intra- and extracellular potassium ion.
BACKGROUND AND OBJECTIVES: With continued advances in treatment options, patients with endoprosthetic reconstruction are living longer and consequently relying upon their devices for a longer duration. Major causes of endoprosthesis failure include aseptic loosening and mechanical failure. In the setting of tumor resection, loss of bone stock and use of radiation therapy increase the risk for these complications. As such, considerations of remaining native bone and stem length and diameter may be increasingly important. We asked the following questions: (1) What was the overall rate of endoprosthesis failure at a minimum of 5-year follow-up? (2) Does resection length increase implant failure rates? (3) Does implant size and its ratio to cortical width of bone alter implant failure rates?
METHODS: We retrospectively analyzed patient outcomes at a single institution between the years of 1999-2022 who underwent cemented endoprosthetic reconstruction at the hip or knee and identified 150 patients. Of these 150, 55 had a follow-up of greater than 5 years and were used for analysis. Radiographs of these patients at time of surgery were assessed and measured for resection length, bone diameter, stem diameter, and remaining bone length. Resection percentage, and stem to bone diameter ratios were then calculated and their relationship to endoprosthesis failure were analyzed.
RESULTS: Patients in this cohort had a mean age of 55.8, and mean follow-up of 59.96 months. There were 78 distal femoral replacements (52%), 16 proximal femoral replacements (10.7%), and 56 proximal tibial replacements (37.3%). There were five patients who experienced aseptic loosening and six patients who experienced mechanical failure. Patients with implant failure had a smaller mean stem to bone diameter (36% vs. 44%; p = 0.002). A stem to bone diameter of 40% appeared to be a breaking point between success and failure in this series, with 90% of patients with implant failure having a stem: bone ratio less than 40%. Stem to bone ratio less than 40% increased risk for failure versus stems that were at least 40% the diameter of bone (6/19 [31.6%] vs. 0/36 [0%]; odds ratio 0.68; p < 0.001). Resection length did not appear to have an impact on the rates of aseptic loosening and mechanical failure in this series.
CONCLUSIONS: Data from this series suggests a benefit to using stems with a larger diameter when implanting cemented endoprostheses at the hip or knee. Stems which were less than 40% the diameter of bone were substantially more likely to undergo implant failure.
Risk Summary

Limited data from published literature report the presence of paliperidone in human breast milk. There is no information on the effects on the breastfed infant, or the effects on milk production; however, there are reports of sedation, failure to thrive, jitteriness, and extrapyramidal symptoms (tremors and abnormal muscle movements) in breastfed infants exposed to paliperidone's parent compound, risperidone (see Clinical Considerations) . Paliperidone has been detected in plasma in adult subjects up to 18 months after a single-dose administration of 3-month paliperidone palmitate extended-release injectable suspension. The clinical significance on the breastfed infant is not known [see Clinical Pharmacology (12.3)] . The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for INVEGA HAFYERA and any potential adverse effects on the breastfed child from INVEGA HAFYERA or from the mother's underlying condition. 

Clinical Considerations

Infants exposed to INVEGA HAFYERA through breastmilk should be monitored for excess sedation, failure to thrive, jitteriness, and extrapyramidal symptoms (tremors and abnormal muscle movements).
PCT No. PCT/EP95/02488 Sec. 371 Date Jan. 9, 1997 Sec. 102(e) Date Jan. 9, 1997 PCT Filed Jun. 24, 1995 PCT Pub. No. WO96/01612 PCT Pub. Date Jan. 25, 1996The present invention deals with a pharmaceutical product in unit dosage form and a unit dosage drug delivery system which comprises a multiple layer capsule or housing having two or more layers, the layers being of materials, wherein the outer layer possesses a hydrophilic character and the inner layer possesses a hydrophobic character, and a capsule filling wherein one or more drug substances are admixed, dissolved, suspended or agglomerated in a hydrophobic support.
The invention relates to a food therapy preparation for preventing and treating cerebrovascular diseases based on the theories of preventive treatment of disease and medicine food homology, which is characterized by comprising the effective ingredients of the following raw materials in weight ratio: 9-11 peach seeds, 4-6 kudzu-vine roots, 4-6 barbary wolfberry fruits, 4-6 fructus alpiniae oxyphyllae, 4-6 cassia seeds and 4-6 hawthorn. The prescription of the food therapy preparation is based on the theory of preventive treatment of disease, and the food therapy preparation is prepared from a sufficient amount of effective ingredients. Although the food therapy preparation is not a medicine, the actions of the medicine can be exerted. The food therapy preparation not only can greatly limit the occurrence and the development of the cerebrovascular diseases, but also can save a great amount of medical resources and investments for China simultaneously. People can conveniently and correctly select the food therapy preparation in a pertinence way according to early symptoms per se, and thus, the purposes of disease prevention and body building are achieved. The food therapy preparation can be directly taken according to a certain amount.
Neurosurgical procedure that mimics the procedure for CERE-120 delivery. No injections were administered during sham surgery.
A clinical pharmacist will be provided as a patient discharges from one of four University of Washington (UW) medical centers to one of 14 post acute skilled nursing facilities randomized to the intervention arm. The coordinating transitional pharmacist will conduct (1) a comprehensive medication review including medication reconciliation, adjustment, and monitoring during the transitional period from hospital to SNF, 2) a structured handoff between clinical teams at the hospital and SNF.
Acute macular neuroretinopathy (AMN) affects the outer retina and is most likely induced by non-inflammatory ischaemia of the retinal deep capillary plexus and choriocapillaris. A man in his early 20s developed Valsalva retinopathy following weightlifting at the gym and presented with blurring of vision in the left eye 1 month after the initial retinal haemorrhages had resolved. A diffuse, purplish, donut-shaped, perifoveal lesion was seen on funduscopy and was well defined by an optical coherence tomography angiography (OCTA) en face image in the left eye. Outer retinal changes on optical coherence tomography (OCT) and a dense co-localised scotoma on a visual field (VF) examination confirmed the diagnosis of AMN, and the patient was started on a tapering dose of oral steroids. Improvement was seen in OCT, OCTA and VF during the 6-month follow-up visit. The use of OCTA en face imaging enabled the accurate identification of the lesion in the affected layers of the retina.
Subscapularis management is an area of controversy in the literature for total shoulder arthroplasty (TSA). Regeneten has been suggested as a bioinductive implant to aid in rotator cuff healing. We hypothesize that applying this technology could aid in obtaining higher rates of subscapularis healing for TSA when utilizing SP or ST, which in turn could lead to improved outcomes.The 50 randomized subjects will be randomized at a 1:1 ratio into the standard subscapularis repair group or the standard repair with Regeneten augmentation group. Subjects will be blinded to their treatment assignment until they complete all study visits. Upon withdraw from the study, termination from the study, or new or recurrent symptoms requiring a subsequent surgical procedure, the blinded assignment will be revealed to the subject. Subjects will be assessed pre-operatively and return post-operatively at Week 2, Weeks 6, Month 3, Month 6, and Year 1. The primary outcome will evaluate subscapularis repair integrity and healing at one year post-op.
PURPOSE: A method for isolating prenylated flavonoid from Cudrania tricuspidata (Call.) Bureau is provided to prevent sample loss. CONSTITUTION: A method for isolating prenylated flavonoid from Cudrania tricuspidata (Call.) Bureau comprises: a step of extracting Cudrania tricuspidata (Call.) Bureau with an organic solvent to prepare an extract; a step of concentrating the extract by centrifugal partition chromatography(CPC). The CPC comprises a step of filling upper phase solvent in a rotor; a step of dropping the upper phase solvent and stabilizing two phases; a step of injecting the extract to prepare a fraction.
OBJECTIVES: There have been significant advances in the management of large (≥20 mm) laterally spreading tumors (LSTs) or nonpedunculated colorectal polyps; however, there is a lack of clear consensus on the management of these lesions with significant geographic variability especially between Eastern and Western paradigms. We aimed to provide an international consensus to better guide management and attempt to homogenize practices.
METHODS: Two experts in interventional endoscopy spearheaded an evidence-based Delphi study on behalf of the World Endoscopy Organization Colorectal Cancer Screening Committee. A steering committee comprising six members devised 51 statements, and 43 experts from 18 countries on six continents participated in a three-round voting process. The Grading of Recommendations, Assessment, Development and Evaluations tool was used to assess evidence quality and recommendation strength. Consensus was defined as ≥80% agreement (strongly agree or agree) on a 5-point Likert scale.
RESULTS: Forty-two statements reached consensus after three rounds of voting. Recommendations included: three statements on training and competency; 10 statements on preresection evaluation, including optical diagnosis, classification, and staging of LSTs; 14 statements on endoscopic resection indications and technique, including statements on en bloc and piecemeal resection decision-making; seven statements on postresection evaluation; and eight statements on postresection care.
CONCLUSIONS: An international expert consensus based on the current available evidence has been developed to guide the evaluation, resection, and follow-up of LSTs. This may provide guiding principles for the global management of these lesions and standardize current practices.